|
Market Closed -
OTC Markets
10:54:58 2026-06-03 EDT
|
5-day change | 1st Jan Change | ||
| 0.0770 USD | -.--% |
|
+8.45% | -16.75% |
| 25-08-29 | Altamira Therapeutics Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 | CI |
| 25-08-29 | Altamira Therapeutics Ltd., H1 2025 Earnings Call, Aug 29, 2025 |
| Market Cap | 529K 654K 562K 482K 900K 61.96M 905K 6.26M 2.42M 31.67M 2.45M 2.4M 101M | P/E 2023 |
-0.44x | P/E 2024 | -0.04x |
|---|---|---|---|---|---|
| Enterprise Value | -109K -135K -116K -99.42K -186K -12.77M -187K -1.29M -499K -6.53M -506K -495K -20.77M | EV / Sales 2023 |
-
| EV / Sales 2024 | - |
| Free-Float |
81.2% | Yield 2023 * |
-
| Yield 2024 | - |
Last Transcript : Altamira Therapeutics Ltd.
| 1 week | +8.45% | ||
| Current month | -8.33% | ||
| 1 month | +23.20% | ||
| 6 months | -18.95% | ||
| Current year | -16.75% |
| 1 week | 0.06 |  | 0.09 |
| 1 month | 0.06 | | 0.09 |
| Current year | 0.05 | | 0.15 |
| 1 year | 0.05 | | 0.15 |
| 3 years | 0.05 | | 17.2 |
| 5 years | 0.05 | | 1,332 |
| 10 years | 0.05 | | 153,600 |
| Manager | Title | Age | Since |
|---|---|---|---|
Thomas Meyer
CEO | Chief Executive Officer | 58 | 2003-03-31 |
Marcel Gremaud
DFI | Director of Finance/CFO | 68 | 2021-10-31 |
Covadonga Pañeda
COO | Chief Operating Officer | 53 | 2022-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Meyer
CHM | Chairman | 58 | 2003-03-31 |
Mats Blom
BRD | Director/Board Member | 61 | 2017-03-31 |
Alain Munoz
BRD | Director/Board Member | 77 | 2018-02-28 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +8.45% | +50.10% | -98.85% | 422K | |
| -2.21% | -3.11% | +52.16% | +91.64% | 1,002B | |
| -2.22% | -0.76% | +51.08% | +67.61% | 649B | |
| -2.99% | -4.31% | +18.59% | +66.94% | 440B | |
| -0.20% | 0.00% | +29.48% | +37.53% | 346B | |
| -0.81% | -15.63% | +8.56% | +25.47% | 263B | |
| -0.42% | -1.29% | -1.29% | +12.57% | 250B | |
| -10.08% | -10.26% | +40.32% | +51.55% | 213B | |
| -0.69% | -4.06% | -14.56% | -57.68% | 201B | |
| -2.88% | -2.19% | +26.54% | +92.95% | 182B | |
| Average | -1.92% | -1.86% | +26.10% | +28.97% | 354.37B | |
| Weighted average by Cap. | -1.35% | -2.39% | +32.78% | +57.62% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | - | - |
| Net income | -3.87M -4.78M -4.11M -3.53M -6.59M -453M -6.62M -45.84M -17.74M -232M -17.96M -17.57M -738M | -8.46M -10.46M -8.99M -7.72M -14.4M -991M -14.48M -100M -38.77M -507M -39.26M -38.41M -1.61B |
| Net Debt | -518K -640K -550K -472K -882K -60.68M -886K -6.13M -2.37M -31.02M -2.4M -2.35M -98.7M | -638K -788K -678K -582K -1.09M -74.72M -1.09M -7.55M -2.92M -38.19M -2.96M -2.9M -122M |
Employees
11
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-08 | US$0.0739 | +4.08% | 12,115 |
| 26-09-03 | US$0.0710 | -.--% | 67,034 |
| 26-09-01 | US$0.0710 | -15.48% | 15,080 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- CYTOF Stock
Select your edition
All financial news and data tailored to specific country editions
